Clinical trial failure or delay for imdusiran and AB-101
The company’s value is concentrated in two HBV programs, so weak data or slow enrollment would materially impair prospects.
- Scope
- Lead pipeline assets
- Materiality
- high
Arbutus Biopharma Corp
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious disease, with its current development efforts centered on chronic hepatitis B. The company’s lead internal programs are imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. In addition to drug development, Arbutus monetizes parts of its intellectual property and delivery technology through collaborations, licenses, and royalty interests. Its business model combines early-stage therapeutic development with technology licensing and royalty income, which helps offset the cash demands of clinical research.
−268,4 %
−237,9 %
+128,2 %
15.73
15.73
| % | |
|---|---|
| Clinical-stage therapeutics | 0% Internal drug candidates in development for chronic hepatitis B, including imdusiran and AB-101. |
| Collaboration and license revenue | 80% Upfront, milestone, and performance-based revenue from partner agreements such as Qilu and other licensing arrangements. |
| Royalty income | 20% Ongoing royalty revenue from ONPATTRO sales and other royalty interests retained by the company. |
| Platform technology licensing | 0% Licensing of Arbutus-owned LNP and ligand conjugate delivery technologies to third parties outside HBV. |
Arbutus does not sell commercial medicines directly to patients; its economic customers are pharmaceutical partners and...
- Strategic pharma partnersprimary
Companies like Qilu that fund development, regulatory work, and commercialization of partnered assets in defined territories.
- Royalty-generating commercial partnersprimary
Commercial product owners whose sales, such as ONPATTRO, generate ongoing royalty income for Arbutus.
- Technology licenseessecondary
Biopharma companies that license Arbutus's LNP and ligand conjugate delivery platforms for non-HBV applications.
- Sublicense and collaboration counterpartiessecondary
Third parties that may commercialize products through Genevant-related sublicenses and revenue-sharing structures.
Arbutus is headquartered in the United States, and its operating footprint is shaped by where its partners develop and...
- •United States headquarters and core corporate decision-making
- •Greater China and Taiwan as the key partnered development/commercialization territory for imdusiran
- •Global royalty exposure through ONPATTRO sales
- •Partner-led manufacturing and commercialization reduce the need for a broad owned footprint
- •Warminster, Pennsylvania headquarters exit reflects restructuring and cost reduction
Arbutus’s current strategy is to maximize the value of its chronic hepatitis B programs while preserving cash and...
01
Advance imdusiran and AB-101medium-term
These are the company’s core internal assets and the main source of long-term therapeutic value.
02
Reduce operating cash burnshort-term
The company remains clinical-stage and needs to preserve liquidity while development timelines remain uncertain.
03
Monetize delivery technologymedium-term
Licensing the LNP platform can generate non-dilutive value from assets outside the core HBV focus.
Arbutus faces the typical risks of a clinical-stage biopharma company: clinical failure, regulatory setbacks, and long...
Patent disputes involving the LNP portfolio
Arbutus’s licensing and royalty leverage depends on enforceable intellectual property, and opponents have challenged key patents.
- Scope
- LNP technology and Genevant-related licensing
- Materiality
- high
Liquidity and financing risk
As a clinical-stage company, Arbutus depends on external funding, partner receipts, and royalty income to support operations.
- Scope
- Corporate cash runway
- Materiality
- high
Revenue concentration and volatility
A large share of revenue comes from a small number of collaboration and royalty sources, making results sensitive to partner performance.
- Scope
- ONPATTRO royalties and Qilu-related revenue
- Materiality
- medium
Revenue recognition for collaboration and license agreements
Can create lumpy quarterly revenue and deferred revenue balances
Royalty revenue measurement
Affects revenue volatility and comparability across periods
Restructuring and exit costs
Can materially affect operating expenses in the period incurred
Arcus Biosciences, Inc.
RCUS · Pharmaceutical Preparations
Arcus Biosciences is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and, to a lesser extent, inflammatory and autoimmune diseases.
ARROWHEAD PHARMACEUTICALS, INC.
ARWR · Pharmaceutical Preparations
Arrowhead Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing RNA interference medicines that silence disease-causing genes.
Barinthus Biotherapeutics plc.
BRNS · Pharmaceutical Preparations
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company built around immune-modulating platforms rather than marketed drugs.
Connect Biopharma Holdings Ltd
CNTB · Pharmaceutical Preparations
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company focused on developing rademikibart, an antibody designed to target IL-4Rα for asthma and COPD.
ARVINAS, INC.
ARVN · Pharmaceutical Preparations
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
: 11/08/2026